Every cancer is different, and scientists have long harboured hopes of developing treatments that can be tailored specifically for each individual patient. And now early results from a final-stage trial of personalised cancer vaccines has the research world holding its breath.US pharmaceutical companies Moderna and Merck have been testing a personalised mRNA vaccine on melanoma patients who had had surgery for their skin cancer. This week, the firms announced that, combined with an established immunotherapy drug, the vaccine had significantly increased the length of time the patients remained cancer-free. This is “a major success in a new field of cancer treatment” that has sent both companies’ shares “surging”, said Reuters.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Join 350,000+ subscribers and keep yourself informed with a selection of
